You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新股IPO | 生物製藥公司岸邁生物明年赴港上市 擬集資至少15億港元
格隆匯 09-08 17:43
格隆匯9月8日丨據IFR引述消息指,內地生物製藥公司岸邁生物(EpimAb Bio)計劃最快明年在港上市,集資額達2到3億美元(約15.55億至23.33億港元)。據悉,高盛及瑞銀正在協調上市事宜。根據官網資料顯示,總部設在上海浦東張江園區的岸邁生物於2016年創立,分別在上海和蘇州設有研發中心和GMP生產基地,目前正針對免疫腫瘤和其他臨牀需求高的領域進行雙特異性抗體系列原創產品的開發。岸邁生物今年3月完成1.2億美元C輪融資,由招銀國際(CMBI)和韓國未來資產基金共同領投,弘毅投資、魚鷹資管、燕創資本、Octagon Capital、新世界(0017.HK)執行副主席兼行政總裁鄭志剛、上灣資本等共同參與。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account